Clinical Pharmacology & Biopharmaceutics
Open Access

Rahul Khairnar

Associate Health Economist at Genentech, San Francisco, California, United States

Biography

An industrious and agile health economics and outcomes research (HEOR) specialist with strong technical expertise in economic evaluations, advanced statistical modeling, comparative effectiveness analyses, patient-centered outcomes research, and observational and clinical trial study designs. Proven aptitude in forming cross-functional partnerships with key internal and external stakeholders including medical, commercial, and field colleagues, therapeutic area experts and key opinion leaders, contract research organizations, and academic research centers.

Publications

An Early Development Budget Impact Model for the Use of Melatonin in the Treatment and Prevention of Osteoporosi

In the U.S., there are approximately 9 million adults with osteoporosis (OP) and an additional 43 million at-risk. By 2030, this number is expected to increase to 68 million adults. The economic impact is estimated to be $23 billion by 2025. Current drug therapies either decrease bone resorption (e.g., bisphosphonates) or stimulate bone formation (... Read More»

Corry D Bondi, Rahul Khairnar, Khalid M. Kamal and Paula Witt-Enderby

Research Article: Clin Pharmacol Biopharm 2015, 4:132

DOI: 10.4172/2167-065X.1000132

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF